| Methods | D: parallel C: unclear B: double WD: 18/94 J: 1‐1‐0 DU: 1m/4m/‐ | |
| Participants | N: 94/76 (89 in safety analysis) D: 37 migraine with and 57 without aura C: World Federation of Neurology Research Group F: 90% A: mean 36 years DU: mean 17 years S: 4 Canadian centers | |
| Interventions | P: 160 mg C: Flunarizine 10 mg | |
| Outcomes | R: 20/39 vs. 25/37 (patient global assessment; threshold used to define positive response not specified; denominators not fully clear, only percentages given) F: slightly better reduction with flunarizine AU: similar reduction HI: not reported AEs: 36/45 vs. 33/44 Dropouts‐AEs: 5/45 vs. 3/44 V: (‐) | |
| Notes | ||
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment (selection bias) | Unclear risk | B ‐ Unclear |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.